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ABSTRACT
Purpose: We aimed to investigate the effects of dupilumab on 1) the permeability and 
antimicrobial barrier, 2) the composition of the skin microbiome, and 3) the correlation 
between changes in skin barrier properties and microbiota in atopic dermatitis (AD) patients.
Methods: Ten patients with severe AD were treated with dupilumab for 12 weeks. Disease 
severity was assessed using the Eczema Area and Severity Index (EASI). Skin barrier function 
was evaluated by measuring transepidermal water loss, stratum corneum (SC) hydration, 
and pH. The following parameters were analyzed in the pre- and post-treatment SC samples; 
1) skin microbiota using 16S rRNA gene sequencing, 2) lipid composition using mass 
spectrometry, and 3) human β-defensin 2 (hBD-2) expression using quantitative reverse 
transcription polymerase chain reaction.
Results: SC hydration levels in the lesional and non-lesional skin increased after 12-week 
dupilumab therapy (24.2%, P < 0.001 and 59.9%, P < 0.001, respectively, vs. baseline) and 
correlated with EASI improvement (r = 0.90, P < 0.001 and r = 0.85, P = 0.003, respectively). 
Dupilumab increased the long-chain ceramide levels in atopic skin (118.4%, P = 0.028 vs. 
baseline) that correlated with changes in SC hydration (r = 0.81, P = 0.007) and reduced 
the elevated hBD-2 messenger RNA levels (−15.4%, P = 0.005 vs. baseline) in the lesional 
skin. Dupilumab decreased the abundance of Staphylococcus aureus. In contrast, the microbial 
diversity and the abundance of Cutibacterium and Corynebacterium species increased, which were 
correlated with an increase in SC hydration levels (Shannon diversity, r = 0.71, P = 0.027; 
Cutibacterium, r = 0.73, P = 0.017; Corynebacterium, r = 0.75, P = 0.012). Increased abundance of 
Cutibacterium species was also correlated with EASI improvement (r = 0.68, P = 0.032).
Conclusions: Th2 blockade-induced normalization of skin microbiome in AD patients is 
associated with increased SC hydration.
Keywords: Atopic dermatitis; dupilumab; stratum corneum hydration; microbiota; ceramides; 
Staphylococcus aureus; Cutibacterium
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INTRODUCTION
Impaired skin barrier function, strong type 2 inflammation, and microbial dysbiosis are 
hallmarks of atopic dermatitis (AD) and their mutual interactions contribute to the onset and 
progression of disease.1
Dupilumab, a monoclonal antibody that selectively inhibits interleukin (IL)-4 receptor-α 
(IL-4Rα) demonstrates clinical improvements in moderate–to-severe AD patients. Inhibition 
of the IL-4/IL-13 signaling targets pathways in both immune cells and epithelial cells 
that are related to the pathogenesis of AD. Indeed, dupilumab has been shown to reduce 
epidermal hyperplasia and upregulate the expression of epidermal differentiation- and lipid 
metabolism-related genes in atopic skin.2 Moreover, recent studies reported a rapid reduction 
in transepidermal water loss (TEWL) in the lesional skin after dupilumab treatment3,4 and 
its correlation with Th2 biomarker thymus and activation-regulated chemokine.3 Despite 
the improvement in dryness in AD patients who received dupilumab treatment clinically, 
previous studies have reported that dupilumab does not increase skin hydration.3,4
In addition to improving inflammatory and barrier impairments, a recent study reported that 
IL-4Rα blockade increases microbial diversity and decreases Staphylococcus aureus colonization 
in the skin of patients with AD.5 This amelioration of cutaneous dysbiosis has been shown 
to correlate with clinical improvement. A systematic review and meta-analysis of 8 studies 
also demonstrated an association of dupilumab treatment with a decreased incidence of skin 
infections and eczema herpeticum in moderate-to-severe AD patients.6 However, it is unclear 
how IL-4/IL-13 blockade results in normalization of dysbiosis and reduction of S. aureus in 
patients with AD.
IL-4 and IL-13 promote S. aureus adhesion by enhancing fibronectin and fibrinogen synthesis7 
and inhibit antimicrobial peptide (AMP) production by keratinocytes in vitro.8,9 These findings 
suggest that Th2 cytokine blockade might reduce S. aureus colonization via modulating 
fibronectin and AMPs production by the skin. However, despite the induction of AMPs in the 
lesional atopic skin, S. aureus is highly colonized, suggesting that altered AMPs expression 
cannot fully explain S. aureus colonization on the skin of AD patients.
Recent evidence indicates that permeability barrier properties also impact the cutaneous 
microbiome.10,11 A mouse model for cutaneous colonization demonstrated that skin barrier 
defects facilitate S. aureus skin colonization and persistence.12 Filaggrin-deficient skin also 
showed decreased bacterial diversity and commensal bacteria, and increased Firmicutes 
abundance, resembling the AD-related pattern.13-15 Moreover, epidermal lipid composition 
has been shown to correlate with bacterial composition.16 These findings support the 
hypothesis that the defective skin barrier promotes colonization of S. aureus and dupilumab 
improves skin barrier functions by inhibiting Th2 inflammation, thereby reducing the 
abundance of S. aureus. To verify this hypothesis, it is necessary to investigate the correlation 
between the improvement of skin barrier properties and microbial dysbiosis during 
dupilumab treatment, but there are few reports investigating their interrelationship.
In this study, we investigated the effects IL-4Rα blockade by dupilumab on the epidermal 
barrier function, stratum corneum (SC) lipid composition, AMP expression, and cutaneous 
microbiome in patients with AD. We also examined the correlation between changes in skin 
barrier properties and microbial composition during dupilumab treatment.
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MATERIALS AND METHODS
Study design and sample collection
All methods were approved by the Institutional Review Board (IRB No.3 -2018-0270) 
of Yonsei University College of Medicine and were performed in compliance with the 
Declaration of Helsinki and Good Clinical Practice. Prior to inclusion, written informed 
consents were obtained from all participants. Ten healthy subjects (mean age, 28.3 years) 
and ten patients with severe AD (mean age, 34.2 years and mean Eczema Area and Severity 
Index [EASI] score, 33.3) were enrolled. All patients initially received 600 mg of dupilumab 
followed by 300 mg every other week. Skin barrier function was measured and SC samples 
were obtained at baseline and after 12 weeks of treatment. Subjects were instructed to avoid 
topical medication and moisturizer application 24 hours prior to sampling. For SC sampling, 
a total of 25 consecutive D-squame tape strips (22 mm diameter; CuDerm, Dallas, TX, USA) 
were collected from the lesional skin of the antecubital fossa. The non-lesional skin samples 
were obtained from the upper inner arm of the same side. Tape strips were stored at −80°C 
until use. The first two tape strips were discarded. Five strips were used to extract DNA for 
16S sequencing (tape strips 3–7), five strips were used for lipidomic analysis (tape strips 8–12), 
and ten strips (tape strips 13–22) were used to extract RNA for real-time quantitative reverse 
transcription polymerase chain reaction (qRT-PCR).
Measurement of skin barrier function
Basal TEWL, SC hydration and skin surface pH were evaluated at baseline and week 12. Basal 
TEWL was measured with a Tewameter (TM210 apparatus; Courage and Khazaka, Cologne, 
Germany). SC hydration was assessed via capacitance with a Corneometer (CM820 device; 
Coruage and Khazaka). Skin surface pH was measured using a pH meter (PH 905; Coruage 
and Khazaka). All measurements were performed by the same trained physician in the same 
room at 20°C-22°C and 20%-40% humidity conditions after 15-30 minutes acclimatization.
DNA extraction and 16S rRNA gene sequencing
SC samples were incubated in a lytic enzymatic mixture of lysozyme, mutanolysin, proteinase 
K, and lysostaphin along with 0.1-mm sterile silica beads to homogenize the samples. 
DNA cleanup was performed with a fecal DNA extraction kit (Zymogen, Irvine, CA, USA). 
The V3V4 variable region of the 16S rRNA gene was PCR-amplified from purified DNA 
and sequenced using the Illumina HiSeq 250-bp paired-reads platform (Illumina Inc., 
Cambridge, UK) as previously reported.17
Metagenomic data analysis
The raw FASTQ files for all samples were demultiplexed based on the barcode. Low-quality, 
merged, and chimeric reads were excluded. The trimmed reads were then merged using 
FLASH v1.2.11 with default parameters. The remainder of the reads (≤97%) were clustered 
de novo into operational taxonomic units (OTUs; using a CD-HIT-EST-based OTU analysis 
program [CD-HIT-OTU]),18 followed by taxonomical classification using the BLASTN v2.4.0 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).19 Only a top BLAST hit with alignment that spanned 
>85% of the original query sequence was assigned. The OTU taxonomies from phylum to 
species were determined based on the NCBI database. QIIME v1.9 was used to analyze 3.33 
million 16S rRNA gene reads, resulting in the identification of 17,725 OTUs at a 97% identity 
level.20 After the removal of rare OTUs, 2,186 OTUs were analyzed. The microbial Shannon 
diversity index was computed in QIIME v1.9 through the whole tree phylogenetic diversity 
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metric.20 Bacterial community profiles at each taxonomic level, from phylum to species, were 
compared using the MetaStats 2.0 package.
Quantification of ceramide N-lignoceroyl-D-erythro-sphingosine (NS)
Human SC tissues collected by the D-squame tape were lysed in RIPA buffer followed by 
extraction of sphingolipids, as we reported previously.21,22 The extracted lipids dried using a 
vacuum system (Vision, Seoul, Korea) were re-dissolved in methanol and analyzed by liquid 
chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS, API 
3200 QTRAP mass; AB/SCIEX, Framingham, MA, USA) by selective ion monitoring mode. 
The ceramide MS/MS transitions (m/z) were 510 → 264 for C14-ceramide, 538 → 264 for 
C16-ceramide, 552 → 264 for C17-ceramide, 566 → 264 for C18-ceramide, 594 → 264 for C20-
ceramide, 648 → 264 for C24:1-ceramide, 650 → 264 for C24-ceramide, 676 → 264 for C26:1-
ceramide, and 678 → 264 for C26-ceramide respectively. All data were acquired using Analyst 
1.5.1 software (Applied Biosystems, Foster City, CA, USA).
Real-time qRT-PCR
Collected tape strips 13-22 from human skin were sequentially scraped into the RLT buffer 
(Qiagen, Mississauga, Canada) on the day of collection and frozen at –80°C. RNA was isolated 
from skin tape strips using RNeasy Micro Kits (Qiagen) according to the manufacturer's 
protocol. After quantification of RNA with a NanoDrop 2000c (Thermo Fisher Scientific, 
Waltham, MA, USA), complementary DNA (cDNA) was synthesized using the cDNA Synthesis 
kit (Thermo Fisher Scientific). TaqMan real-time PCR assays (Applied Biosystems) were 
performed to analyze the messenger RNA (mRNA) levels. A TaqMan probe for hBD-2 (DEFB4A) 
(Thermo Fisher Scientific) was used. The relative gene expression was normalized to the mean 
level of glyceraldehyde 3-phosphate dehydrogenase mRNA (Thermo Fisher Scientific).
Statistical analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, 
CA, USA). A paired t-test was used for analysis of qRT-PCR data. Mann-Whitney or Wilcoxon 
rank-sum test were used for analysis of barrier parameters and to determine differences in 
microbial alpha diversity and abundance of individual taxa between pre- and post-treatment 
skin. We calculated the Spearman correlation of percentage change from baseline to week 
12 in EASI scores or C26 ceramide amounts with percentage change from baseline in SC 
hydration levels at week 12 and evaluated the correlation of percentage change from baseline 
to week 12 in EASI scores or SC hydration levels with change in Shannon diversity index 
or the relative abundance of individual bacterial taxa from baseline to week 12 by using 
Spearman correlation coefficients. P  < 0.05 was considered significant.
RESULTS
Dupilumab increases SC hydration and long-chain ceramide (C26) levels in 
patients with AD
We first assessed the effect of dupilumab on epidermal permeability barrier function. SC 
hydration levels in both lesional and non-lesional skin of patients with AD significantly 
increased from baseline to week 12 (24.2%, P < 0.001 and 59.9%, P < 0.001, respectively, vs. 
baseline) (Fig. 1A). Decreases in basal TEWL was observed in the lesional (−26%, P = 0.006, 
vs. baseline) but not in the non-lesional skin by week 12. Skin surface pH in the lesional and 
the non-lesional skin did not significantly change from baseline at week 12 (Fig. 1A). We also 
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analyzed changes in SC ceramide subclasses in dupilumab-treated patients with AD using 
high-performance LC-ESI-MS/MS. Remarkably, the amount of C26 in the lesional and the 
non-lesional skin significantly increased at week 12 (118.4%, P = 0.029 and 25%, P = 0.043, 
respectively, vs. baseline) (Fig. 1D).
We then evaluated whether changes in SC hydration and C26 at week 12 correlate with the 
clinical response to dupilumab. The mean EASI score decreased by 72.5% at week 12 (P < 
0.001, vs. baseline) (Fig. 1B). Percentage change in SC hydration levels in both lesional (r = 
0.9, P < 0.001) and non-lesional (r = 0.851, P = 0.003) skin to week 12 was highly correlated 
with percentage change in EASI scores from baseline to week 12 (Fig. 1C). However, the 
percentage changes in basal TEWL in the lesional skin and C26 ceramide amounts in the 
lesional and the non-lesional skin from baseline to week 12 were not significantly correlated 
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Fig. 1. Changes in skin barrier function and SC ceramide content in patients with AD following dupilumab treatment. (A) Changes in TEWL, SC hydration, and 
skin surface pH in lesional and non-lesional skin from baseline to week 12. (B) EASI scores before and after treatment. (C) Correlation between the percentage 
change in SC hydration levels from baseline to week 12 and the percentage decline in EASI scores at week 12. (D) Liquid chromatography electrospray ionization 
tandem mass spectrometry analysis of the ceramide levels in SC of the lesional and non-lesional skin before and after dupilumab treatment. (E) Correlation 
between the percentage changes in C26 ceramide contents and SC hydration levels from baseline to week 12 in the lesional skin. Data are expressed as mean ± 
standard error of mean. 
SC, stratum corneum; TEWL, transepidermal water loss; EASI, eczema area and severity index; B, baseline; 3M, 3 months of treatment; AD, atopic dermatitis. 
*P < 0.05; †P < 0.01.
with the EASI reduction. Percentage change in C26 ceramide amounts from baseline to week 
12 was significantly correlated with percentage change in SC hydration levels from baseline to 
week 12 in the lesional skin (r = 0.806, P = 0.007) (Fig. 1E).
Human β-defensin 2 (hBD-2) mRNA levels in SC are upregulated in the 
lesional AD skin and decreased after dupilumab treatment
hBD-2 mRNA expression levels in the lesional and the non-lesional SC samples of patients 
with AD were quantified by using real-time qRT-PCR before and after dupilumab treatment. 
At baseline, the mRNA expression levels of hBD-2 were higher in the lesional skin than in the 
non-lesional skin and the normal skin of healthy controls (HC) (fold change 1.32 vs. non-
lesional skin and fold change 1.56 vs. HC, all P < 0.05). After treatment, hBD-2 levels in the 
lesional skin decreased from baseline to week 12 (−15.4%, P = 0.005), while hBD-2 levels in 
the non-lesional skin showed no significant change (Fig. 2).
Dupilumab alters the microbiota composition in atopic skin
We next investigated dupilumab-induced changes in cutaneous microbiome profiles. Tape 
strips were collected from the lesional and the non-lesional skin from patients with AD 
before and after 12 weeks of dupilumab treatment. At baseline, the lesional and the non-
lesional skin showed a reduced microbial diversity (alpha diversity), assessed by Shannon 
diversity index (lesional skin, 2.9; non-lesional skin, 3.34; HC, 4.49; P = 0.008 and 0.01 
for the lesional skin vs. HC and the non-lesional skin vs. HC, respectively). Dupilumab 
significantly increased bacterial diversity in both lesional (baseline, 2.9 vs. week 12, 4.4, P = 
0.005) and non-lesional (baseline, 3.34 vs. week 12, 4.6, P = 0.004) skin at week 12 to levels 
comparable with those of the HC (Fig. 3).
We then examined the changes in relative abundance of individual bacterial taxa at the 
phylum and genus levels following treatment. The abundance of Staphylococcus spp. was 
higher in the lesional and the non-lesional skin, while that of certain skin commensals, 
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Fig. 2. Comparison of hBD-2 mRNA (DEFB4A) levels before and after dupilumab treatment. Expression of hBD-2 
mRNA (DEFB4A) is increased in lesional skin at baseline and decreased at 12 weeks of dupilumab treatment. 
The mRNA expression levels of hBD-2 in lesional and non-lesional stratum corneum samples of patients with AD 
before and after dupilumab treatment were analyzed using quantitative reverse transcription polymerase chain 
reaction. Data are expressed as mean ± standard error of mean. 
HC, healthy control; mRNA, messenger RNA; L, lesional; NL, non-lesional; hBD-2, human β-defensin 2; AD, 
atopic dermatitis. 
*P < 0.05.
including Cutibacterium spp. and Lactobacillus spp. was lower in the lesional skin than in the 
healthy skin at baseline (Fig. 4A). The relative abundance of S. aureus significantly decreased 
from baseline to week 12 in the lesional (33.4% vs. 13.3%, P = 0.049) and the non-lesional 
(29.7% vs. 10.3%, P = 0.016) skin following treatment (Fig. 4B and C). Furthermore, significant 
increases in the relative abundance of Lactobacillus spp. (0.08% vs. 0.59%, P = 0.003) and major 
skin commensals including Cutibacterium spp. (1.1% vs. 3.58%, P = 0.005) and Corynebacterium 
spp. (5.9% vs. 11.6%, P = 0.005) were seen at week 12 in the lesional skin (Fig. 4B).
Increases in SC hydration correlate with increases in the microbiota diversity 
and proportion of major commensal microbes following dupilumab treatment
Then, we assessed the correlation between changes in microbial composition, barrier 
properties, and disease severity from baseline to week 12 (Fig. 5A). An increase in the 
Shannon diversity index and decrease in the relative abundance of S. aureus in the lesional 
skin were not significantly correlated with EASI improvement. Instead, the increased relative 
abundance of Cutibacterium spp. to week 12 was significantly correlated with the decline in 
EASI score following treatment (r = 0.677, P = 0.032) (Fig. 5B).
Remarkably, we observed a significant positive correlation between the change in SC 
hydration levels and the increase in Shannon diversity index from baseline to week 12 in the 
lesional skin (r = 0.709, P = 0.027). An increase in SC hydration levels from baseline to week 
12 was also significantly correlated with the increase in the relative abundance of Cutibacterium 
spp. (r = 0.729, P = 0.017) and Corynebacterium spp. (r = 0.754, P = 0.012) to week 12 in the 
lesional skin (Fig. 5C). However, there was no significant correlation between changes in 
S. aureus abundance and SC hydration. Moreover, the increase in the relative abundance 
of Cutibacterium spp. (r = 0.746, P = 0.017) and Corynebacterium spp. (r = 0.770, P = 0.013) in 
the lesional skin from baseline to week 12 was significantly correlated with an increase in 
Shannon diversity index (Fig. 5D).
There was no significant correlation between change in the amounts of C26 ceramide with 
either change in bacterial diversity or relative abundance of individual taxa following treatment.
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Fig. 3. Changes in microbiota α diversity (Shannon diversity index) in atopic lesional and non-lesional skin before 
and after 12 weeks of dupilumab treatment. Data are expressed as mean ± standard error of mean. 
HC, healthy control; L, lesional; NL, non-lesional; AD, atopic dermatitis. 
*P < 0.05; †P < 0.01.
DISCUSSION
We demonstrated that IL-4/IL-13 blockade with dupilumab increased SC hydration in both 
lesional and non-lesional skin in patients with AD. Moreover, this increase in SC hydration 
levels was significantly correlated with improvement in disease severity. At the lesional 
skin, dupilumab also reduced TEWL at week 12, however, there was no significant change 
of skin surface pH from baseline. These findings suggest that SC hydration is an important 
biophysical parameter of skin barrier function to predict or monitor the response to anti-
IL-4/IL-13 therapy in patients with AD. Decreased levels of the filaggrin breakdown products 
and reduced production of ceramides in SC cause dry skin in patients with AD.23-25 Notably, 
dupilumab increased C26 content in atopic skin, in line with a previous report showing that 
dupilumab upregulates ELOVL3 gene expression.2 In addition, change in C26 contents at 
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Fig. 4. Changes in skin microbiome in patients with AD before and after 12 weeks of dupilumab treatment. (A) Relative abundance of major taxa in non-lesional 
and lesionl atopic skin before and after dupilumab treatment. (B) Relative abundance of S. aureus, Lactobacillus spp., Cutibacterium spp., and Corynebacterium 
spp. in atopic lesional skin and (C) S. aureus in atopic non-lesional skin before and after dupilumab treatment. The center line in the box plots corresponds to 
the median. 
L, lesional; NL, non-lesional; AD, atopic dermatitis.
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Fig. 5. Correlation between changes in EASI, SC hydration, bacterial diversity and relative abundance of major taxa following dupilumab treatment. (A) Heat map 
of the overall correlation matrix. Colors display the strength of correlation based on Spearman's correlation coefficient in each pair of biomarkers. Significant 
correlations (corrected P < 0.05) are indicated with yellow boxes. (B) Correlation between the percentage change in EASI scores from baseline to week 12 and 
changes in Shannon diversity index, relative abundance (%) of S. aureus, and relative abundance (%) of Cutibacterium in lesional skin following 12 weeks of 
dupilumab treatment. (C) Correlation between the percentage change in SC hydration levels from baseline to week 12 and changes in Shannon diversity index, 
relative abundance (%) of S. aureus, and relative abundance (%) of Cutibacterium in lesional skin following 12 weeks of dupilumab treatment. (D) Correlation 
between changes in Shannon diversity index from baseline to week 12 and changes in the relative abundance (%) of Corynebacterium and Cutibacterium in lesional 
skin following 12 weeks of dupilumab treatment. The linear regression curve fit, Spearman's correlation coefficient r, and P values are shown for each graph. 
EASI, eczema area and severity index; SC, stratum corneum; AD, atopic dermatitis.
week 12 significantly correlated with change in SC hydration levels at week 12 in the lesional 
skin. These findings suggest that the increased level of C26 is a potential mechanism by 
which dupilumab increases SC hydration. Importantly, dupilumab increased SC hydration 
and long-chain ceramide content not only in the lesional skin, but also in the non-lesional 
skin, suggesting that Th2 blockade can prevent the recurrence or progression of AD by 
enhancing permeability barrier function in the non-lesional skin.
While our results are consistent with previous data demonstrating a reduction of TEWL 
following dupilumab treatment in the lesional skin,3,4 our findings differ from a recent study 
by Furuhashi et al.4 in that the SC hydration was transiently increased at head and neck area 
within week 14, but was not increased across diverse body sites during 24 weeks of dupilumab 
treatment in Japanese patients with AD. This difference may be partially due to the fact that 
our study measured barrier function only at the initial time point (week 12). In addition, 
barrier impairment in AD patients is related to inherited FLG mutations as well as Th2 
inflammation. The frequency of FLG mutations in Koreans (14%-16%) with AD is lower than 
that in other Asian countries (up to 27%) and Europe (up to 50%),26,27 suggesting that barrier 
defects in Korean AD patients are more likely to be caused by Th2 inflammation rather than 
inherited FLG mutations. Therefore, improvements of barrier defects by Th2 blockade are 
more likely to occur in Korean AD patients than in other populations with a high frequency 
of FLG mutations. To clarify these issues, a long-term study of more patients, along with 
information on the FLG mutation is needed.
Cutaneous dysbiosis that is characterized by the colonization of S. aureus and a loss of other 
commensal microbes such as Staphylococcus epidermidis and Corynebacterium spp. affects the 
onset and progression of AD, and vice versa.28,29 We observed a decreased colonization of S. 
aureus and increased bacterial diversity in both lesional and non-lesional skin of dupilumab-
treated AD patients, as reported previously.5 This normalization of cutaneous dysbiosis 
following IL-4/IL-13 blockade may result from several mechanisms: alteration in epidermal 
permeability or antimicrobial barrier or direct effect of Th2 blockade on the S. aureus 
adhesion. To understand how Th2 blockade decreases S. aureus colonization, we assessed 
change in hBD-2 expression in dupilumab-treated skin of patients with AD. Consistent with 
previous studies,30-33 SC in the lesional skin had higher hBD-2 levels than the non-lesional and 
the control skin. After treatment, a significant reduction in hBD-2 levels was observed in the 
lesional skin. This result is inconsistent with the previous findings that IL-4 and IL-13 inhibit 
hBD-2 upregulation in TNF-α- and IFN-γ-stimulated keratinocytes in vitro.34 However, the 
regulation of hBD-2 in atopic skin in vivo is more complex because IL-17 and IL-22, the potent 
AMP inducers in keratinocytes, are also increased in atopic skin.35-37 Moreover, a previous 
study reported that dupilumab downregulated Th17- and Th22-regulated genes in the lesional 
atopic skin.2 Together, our data suggest that elevated hBD-2 levels in the lesional SC result 
from atopic skin inflammation, and the reduction in hBD-2 by dupilumab is possibly due to 
its anti-inflammatory effects beyond the known Th2-driven inflammation. These findings 
also suggest that the dupilumab-induced decrease in S. aureus colonization in the lesional skin 
is not due to upregulation of hBD-2, one of the most efficient AMPs.
Instead, we found an increase in the relative abundance of major skin commensals in 
dupilumab-treated lesional skin, which has not been observed in previous studies. 
Remarkably, an increase in Cutibacterium abundance was strongly correlated with clinical 
improvement. Growing evidence suggests that commensal bacteria can inhibit pathogenic 
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S. aureus by producing antimicrobial substances or activating host defense mechanisms.11,38-41 
Cutibacterium spp. produce thiopeptides that are homologous to berninamycin and have 
antibacterial activity against Staphylococcus.42 Certain strains of Corynebacterium spp. release 
free fatty acids with antibacterial activity from the skin surface lipids.43 Moreover, S. aureus 
was inversely correlated with the abundance of Cutibacterium spp. and Corynebacterium spp. 
in atopic skin.44-46 Additionally, dupilumab elevated the Lactobacillus spp. abundance in this 
study. The probiotic Lactobacillus spp. regulates the gut microbial population and function. 
Despite its low abundance in the skin, a recent study showed that Lactobacillus spp. inhibits 
S. aureus growth in vitro and topical application of live Lactobacilli on the skin of patients with 
acne reduces Staphylococcus colonization.47 These findings suggest that increased abundance 
of the commensals is a possible mechanism contributing to the observed decrease in S. aureus 
abundance following IL-4/IL-13 blockade. Although we did not observe a negative correlation 
between dupilumab-induced changes in the abundance of S. aureus and these commensals, 
increases in Cutibacterium spp. and Corynebacterium spp. were significantly correlated 
with increased bacterial diversity. Whether and how these commensals control S. aureus 
colonization in vivo needs to be analyzed further.
We also found that increases in Shannon diversity and the relative abundance of Cutibacterium 
spp. and Corynebacterium spp. were highly correlated with increases in SC hydration. These 
findings suggest that dupilumab-induced increase in SC hydration levels affect bacterial 
composition, leading to increased abundance of major commensals and bacterial diversity. 
However, the significant correlations between SC hydration and improvements of skin 
dysbiosis could be results of improvements of skin Th2 inflammation by dupilumab 
treatment (epiphenomenon). The possibility of a causal relationship between changes in SC 
hydration and microbiome composition should be explored in future studies.
Unlike change in SC hydration levels, change in C26 contents did not significantly correlate 
with change in microbiome configuration. However, we found a significant correlation 
between the change in C26 ceramides with the change in SC hydration levels during 
dupilumab treatment, suggesting that the increase of C26 by Th2 blockade is associated 
with the increase in SC hydration, but the increase of C26 ceramide alone could not directly 
affect the improvement of dysbiosis. Epidermal lipid composition is known to affect bacterial 
community configuration,16 but it is presumed that lipid components other than long-chain 
ceramides are also involved in microbiome configuration in a complex manner. Further 
studies with more subjects are needed to more accurately understand the relationship between 
changes in lipid profile and changes in the microbiome following dupilumab treatment.
The limitation of our study is the small sample size. Nevertheless, we could identify 
significant improvement in skin barrier properties, microbiome composition, and a 
significant correlation between changes in SC hydration and microbiota following dupilumab 
treatment. Another potential limitation of our study was the lack of age- and sex-matched 
placebo control group in AD patients when evaluating changes in skin microbiome by 
dupilumab. Longitudinal data from AD patients receiving dupilumab and placebo would 
provide more accurate characterization of the changes in skin microbiota associated with 
dupilumab treatment. Finally, we were unable to analyze various AMPs other than hBD-2 
with potent antimicrobial properties in relation to S. aureus because the SC samples were 
not sufficient for analysis. It would be valuable to analyze other AMPs such as hBD-3 and 
cathelicidin in patients with AD during dupilumab treatment.
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In conclusion, IL-4Rα blockade increases SC hydration levels and long-chain ceramides in 
the lesional and the non-lesional skin of AD patients. We also found a decreased abundance 
of S. aureus, while increases in skin commensals in dupilumab-treated atopic skin. Our 
correlation data suggest that dupilumab-induced improvement in dysbiosis with decreased S. 
aureus colonization is associated with increased SC hydration and proportions of major skin 
commensals, but not with changes in hBD-2 production. Further research is needed on the 
causal relationship between changes in SC hydration and microbiome composition and the 
effects of increased skin commensal populations (Cutibacterium and Corynebacterium spp.) on 
improving AD during dupilumab treatment.
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